Accelerate Diagnostics Inc (NASDAQ:AXDX) — Market Cap & Net Worth
Market Cap & Net Worth: Accelerate Diagnostics Inc (AXDX)
Accelerate Diagnostics Inc (NASDAQ:AXDX) has a market capitalization of $859.92K ($859.92K) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30786 globally and #6249 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Accelerate Diagnostics Inc's stock price $0.04 by its total outstanding shares 25291700 (25.29 Million). Also see how large is Accelerate Diagnostics Inc's balance sheet for a full breakdown of the balance sheet.
Accelerate Diagnostics Inc Market Cap History: 2015 to 2025
Accelerate Diagnostics Inc's market capitalization history from 2015 to 2025. Data shows change from $5.44 Billion to $1.01 Million (-58.06% CAGR). Also see Accelerate Diagnostics Inc (AXDX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Accelerate Diagnostics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #906 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2875 of 3165 |
Weight: Accelerate Diagnostics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Accelerate Diagnostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Accelerate Diagnostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AXDX stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.59x
Accelerate Diagnostics Inc's market cap is 2.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.44 Billion | $147.00K | -$45.50 Million | 36974.06x | N/A |
| 2016 | $5.25 Billion | $246.00K | -$66.37 Million | 21333.45x | N/A |
| 2017 | $6.63 Billion | $4.18 Million | -$62.88 Million | 1586.41x | N/A |
| 2018 | $2.91 Billion | $5.67 Million | -$88.33 Million | 512.97x | N/A |
| 2019 | $4.27 Billion | $9.30 Million | -$84.31 Million | 459.75x | N/A |
| 2020 | $1.92 Billion | $11.16 Million | -$78.21 Million | 171.71x | N/A |
| 2021 | $1.29 Billion | $11.78 Million | -$77.70 Million | 109.69x | N/A |
| 2022 | $178.56 Million | $12.75 Million | -$62.49 Million | 14.00x | N/A |
| 2023 | $99.14 Million | $12.06 Million | -$61.62 Million | 8.22x | N/A |
| 2024 | $30.35 Million | $11.70 Million | -$50.05 Million | 2.59x | N/A |
Competitor Companies of AXDX by Market Capitalization
Companies near Accelerate Diagnostics Inc in the global market cap rankings as of September 18, 2026. Review AXDX tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Accelerate Diagnostics Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #229 globally with a market cap of $109.23 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.99 Billion | $102.36 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.60 |
| #229 | Stryker Corporation | NYSE:SYK | $109.23 Billion | $284.76 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Accelerate Diagnostics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Accelerate Diagnostics Inc's market cap moved from $5.44 Billion to $ 1.01 Million, with a yearly change of -58.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.01 Million | -96.67% |
| 2024 | $30.35 Million | -69.39% |
| 2023 | $99.14 Million | -44.48% |
| 2022 | $178.56 Million | -86.18% |
| 2021 | $1.29 Billion | -32.59% |
| 2020 | $1.92 Billion | -55.15% |
| 2019 | $4.27 Billion | +46.96% |
| 2018 | $2.91 Billion | -56.11% |
| 2017 | $6.63 Billion | +26.27% |
| 2016 | $5.25 Billion | -3.44% |
| 2015 | $5.44 Billion | -- |
End of Day Market Cap According to Different Sources
On May 14th, 2026 the market cap of Accelerate Diagnostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $859.92K USD |
| MoneyControl | $859.92K USD |
| MarketWatch | $859.92K USD |
| marketcap.company | $859.92K USD |
| Reuters | $859.92K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-po… Read more